Impact of Induction Therapy Type
The most commonly immunosuppressant used was Basiliximab (57.2%, n=4,886) followed by thymoglobulin (32.5%, n=2,775) (Supplementary Table 3). A sub-analysis that evaluated patients who received induction therapy with either Thymoglobulin or Basiliximab (n=7,661) indicated that risk-adjusted odds were comparable between the type of induction therapy for drug-treated rejection at 1-year, renal failure requiring dialysis, and mortality at all time intervals (Supplementary Table 4)